Crossmark

GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective

Crossref DOI link: https://doi.org/10.1007/s13300-019-0642-2

Published Online: 2019-06-10

Published Print: 2019-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Rasalam, Roy https://orcid.org/0000-0002-6822-7936
Barlow, John

Kennedy, Mark

Phillips, Pat

Wright, Alan
Funding

Funding for this research was provided by:

Eli Lilly Australia
License Information

Text and Data Mining valid from 2019-06-10

Version of Record valid from 2019-06-10
More Information

Article History

Received: 1 May 2019

First Online: 10 June 2019